Vaginal multipurpose prevention technologies: promising approaches for enhancing women’s sexual and reproductive health
- 17 February 2020
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 17 (3) , 379-393
Abstract
Introduction: Multipurpose prevention technologies (MPTs) have the potential to avert multiple concomitant sexual and reproductive health issues in women such as sexually transmitted infections and unintended pregnancy. MPTs incorporate one or more active pharmaceutical ingredients in a single product, which adds more convenience for users and may promote increased adherence. Various vaginal dosage forms/delivery systems have been studied for designing MPTs. However, several challenges remain that are mainly related with requirements of individual drugs or intended multiple applications. Areas covered: This review focuses on the emerging need and development of vaginal MPTs. It illustrates numerous examples that are currently in the pre-clinical and clinical development pipeline, highlighting the concept behind vaginal MPTs. The article also highlights the challenges associated with formulation design and development, including regulatory issues that need to be addressed. Expert opinion: Vaginal MPTs present great potential to empower women with novel, efficient and safe products for protection against sexually transmitted infections and unintended pregnancy. However, several technological issues and regulatory gaps still need to be addressed in order to meet real world needs.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (POCI-01-0145-FEDER-007274)
- NORTE2020 (NORTE-01-0145-FEDER-000012)
This publication has 120 references indexed in Scilit:
- Measurement of Mucosal Biomarkers in a Phase 1 Trial of Intravaginal 3% StarPharma LTD 7013 Gel (VivaGel) to Assess Expanded SafetyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Variations in microbicide gel acceptability among young women in the USA and Puerto RicoCulture, Health & Sexuality, 2012
- pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmissionEuropean Journal of Pharmaceutics and Biopharmaceutics, 2011
- Formulation of tenofovir‐loaded functionalized solid lipid nanoparticles intended for HIV preventionJournal of Pharmaceutical Sciences, 2011
- Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004)AIDS, 2011
- The Importance of Male Partner Involvement for Women’s Acceptability and Adherence to Female-Initiated HIV Prevention Methods in ZimbabweAIDS and Behavior, 2010
- Vaginal microbiome of reproductive-age womenProceedings of the National Academy of Sciences, 2010
- Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than virusesProceedings of the National Academy of Sciences, 2009
- Covert Use, Vaginal Lubrication, and Sexual Pleasure: A Qualitative Study of Urban U.S. Women in a Vaginal Microbicide Clinical TrialArchives of Sexual Behavior, 2009
- Microbicide safety/efficacy studies in animals: macaques and small animal modelsCurrent Opinion in HIV and AIDS, 2008